Pharmaceutical Company

Solopharm

We care for people



ver. 5.9 from 10.10.2024

SOLOPHARM

Solopharm mission and values

>

To create modern, high-quality and affordable pharmaceuticals to preserve people's health and quality of life



High-quality

We strive for the highest quality

in all aspects of our work: production, management, partnership

Caring for people

People are the key value of the company: consumers, employees, partners, investors



Sustainability

Rational use of resources allows us to maintain affordable prices and provide the maximum number of people with a quality treatment

Solopharm today

SOR

-

History of the company

Liquid Plant foundation and construction

2014 - 2017

- Launch of the 1st stage. Production of the first batch of infusion solutions
- Launch of the 2nd stage. Production of ophthalmic and nasal products
- Launch of the 3rd stage of the plant 10 new lines

2019

MDI aerosol line was launched

2020

Start of construction of a new plant for solid dosage forms manufacturing



<mark>Գ **2021**</mark>

- Launch of the biotechnological developments' laboratory and pilot scale site
- Production line EVA2 increasing the capacity for the pre-filled syringes production
- Launch of the 1st stage of the food supplements production (stick packs)

2022

Launch of the solid dosage forms plant

2023

Launch of the 4th stage of the liquid dosage form plant. Increasing the manufacturing facilities

- Launch of Matrix Wall design and manufacture of clean rooms
- Launch of the 2nd stage of the food supplements plant (capsules)
- Groundbreaking of the Hormones plant (production of hormonal drugs)
- Launch of the 1st stage of the solid plant

2024

- Launch of the ESS pharmaceutical warehouse
- Launch of a new plant for soft dosage forms manufacturing

4

S Our team

470 0 Office

905

Production

65 1111

Warehouse

101 R&D department

nad departmen



Regional staff



Solopharm team

Is a team of professional and likeminded individuals who strives to create the best on the Russian market and can respond flexibly to global challenges

Ready to cooperate

Every year more than **150 people** complete an internship in our company. More than **40 corporate events** are conducted

2013	2015	2019	2022	2023	2024
49	311	1042	1739	1900	1870
employees	employees	employees	employees	employees	employees

General structure of the company





SOLOPHARM

Solopharm partnership with the professional community

>

Professional interaction with medical community and pharmacy segment is aimed to increase the knowledge of specialists and final customers about the company and its products

> 300 regional staff

Promotion teams:

- Ophthalmology
- ENT and therapy
- Rheumatology
- Cosmetology
- Neurology

>250

cities of presence



>70 000

physicians and pharmacists receive up-to-date information about Solopharm products every year

SOLOPHARM

Solopharm Ranking



*According to the results by the end of 7 months 2024, based on IQVIA and DSM Group data (including medical products segments, food supplements: Sea water, dry eye syndrome, Armaviscon, AquaOptic, Olyfrin, Ingasalin.

**According to the results by the end of 7 months 2024. In government contract prices (VAT included), only 44-FZ. The period is determined by the auction date, the government contract status is «completed» and «completed/not conducted» According to IQVIA, for infusions, conversion to packaging No.1

Company through the eyes of the analytical agencies/ 2023-2024

> TOP 10 manufacturers in the retail segment*

> №1 in the ophthalmic market segment in value terms among all manufacturers on the Russian market**

- > Nº3 in the overall rating of all manufacturers***
- > №1 in the ranking of manufacturers in the target market****

Solopharm products*****

> №1 in the recommendations of ophthalmologists of Russia

> №1 in the recommendations of otorhinolaryngologists of Russia

> N₂3 in the recommendations of pediatricians of Russia

*According to AlphaRM, 3 months 2024, in the retail segment (sales from pharmacies) **According to IQVIA and DSM Group, 2023, retail (Medical devices + Drugs) ***According to Ipsos, May 2024, data on doctors' prescriptions ****According to Ipsos, May 2024, data on medical prescriptions (us + competitors) *****According to Ipsos Prindex, Q1 2024

Single quality standard

V

All Solopharm production sites are built in accordance with the GMP standards



Conclusion of compliance with the Rules of the good manufacturing practice

NºGMP/EAEU/RU/00805-2023

Quality management system certificates:

- Certificate RU24/00000044GMP Codex Alimentarius General Principles of Food Hygiene CAC/RCP-1-1969, Rev.5 (2022)
- ISO 13485:2016 (UAE)

International recognition of Solopharm products

CPhI Awards short list nominee 2018.

Category: «Excellence in Pharma: OTC» Belarus Kazakhstan Mongolia Georgia vrqyzs Armenia Tajikistan Turkmenistan Morocco Egypt Kuwait Azerbaijan Qatar Vietnam Mexico Saudi Arabia UAE Cambodia Brazil



Our products are presented

Supply horizons: > Brazil > UAE > Egypt > Mexico



> Turkmenistan



Research and Development / R&D

V

R&D Department provides full cycle of the pharmaceutical development: from idea to technology implementation into the production process



269

market authorizations in more than 15 highly demanding therapeutic areas

26

products and medical devices in the process of authorization

157

products under development

SOLOPHARM

Solopharm Quality Control

Solopharm has its own laboratories that control the quality of all incoming raw materials at all manufacturing stages as well as the quality of the finished products



Microbiological laboratory

4 657 tests per week

microbiological control of the manufacturing environment, materials and finished products Analytical laboratory


6674 tests per week

quality control of raw materials, packaging and printed materials, in-process control and quality control of finished products **Certification department**

146 tests per week

finished products release with quality certificates

Solopharm products are presented in various in-demand areas





Food supplements





more than 250 drug products

are included in the portfolio in various therapeutic areas

13

SOLOPHARM

Solopharm production sites

CUIC

ant

50

Eva

S

Solopharm Liquid Plant

The largest manufacturer of liquid dosage forms in Russia

>190 medicines under production

28

production lines with high automation level





product units per year

Innovative dosage forms

help maintain the sterility of the products, guaranteeing high-quality and safety for the consumer

Solopharm Liquid Plant

V

Liquid Plant has been built in accordance with the GMP standards

21 500 m²

total floor area of the plant

8 248 m²

clean room floor area

1 100 000 I/day

capacity of the water treatment system

1 098 000 m³/h

capacity of the air treatment system

3,14 мw

electrical power of production



Innovative release forms and technologies

Help maintain the sterility of medicines, ensuring high quality and safety

	Pre-filled syringes	BOV technology [Bag-On-Valve]	OSD bottle [Ophthalmic Squeeze Dispenser]				
/S							
	Ready-to-use drug	The drug is in a sealed bag inside an aerosol can	Two systems of air filtration				
	Reinforced syringe stem and reinforced stop for comfortable use	Sprays continuously and works at any angle	Guarantees sterility of the product without the use of preservatives				


Release forms

- BFS infusion bottles
- BFS injection ampoules
- CBP injection ampoules
- BFS unidoses
- metered drops and sprays
- multidose bottles
- OSD bottles
- BOV aerosols
- MDI aerosols
- pre-filled syringes
- etc.

SOLOPHARM

even after opening

Innovative release forms and technologies



Preservative-free metered sprays

Unique nozzle technology


Precise dosing and wide geometry of spraying

BFS technology
[Blow-Fill-Seal]

Polymer ampoules

Ease of storage and transportation, noninvasiveness usage

MDI technology [Metered Dose Inhaler]




Metered aerosol for inhalation

Rapid drug delivery to the respiratory system organs

Solopharm production sites

11

S



11

shin minerelle

William

Carl S

Пескара

The second second

Solic plant

Solopharm Solid Plant

S

New modern plant for the production of solid dosage forms

3

production lines with high automation level **1,3** bln tablets per year

115

medicines under development and registration and in the process of authorization

Solopharm Solid Plant

V

Solid Plant has been built in accordance with the GMP standards

 $12\,257\,{}_{m^2}$

total floor area of the plant

>9 600 m²

clean room floor area





electrical power of production

Ventilation:

The air treatment system meets international GMP standards, which ensures D class in the rooms


Solopharm Solid Plant

S

The modular system of clean rooms

spaced at intervals of 1200 mm made of glass and steel allows quickly transferring the walls and changing the ceiling height







All engineering systems supporting the operation of the production lines are located in the serviced ceiling space



The ventilation system automatically maintains humidity, temperature and differential pressure, ensuring the clean room class

Solopharm production sites

Biotech

Biotech

Site for the development and production of biotechnological products

13 projects under development

- Oncology
- Autoimmune diseases
- Ophthalmology

1

production line



2

laboratories:

- > bioprocess development
- > analytical methods

High-tech equipment from the international manufacturers

- > Bioreactor systems
- > Cryostorage systems
- > Chromatographs, etc.

SOLOPHARM

S Biotech

1 300 m² total area

448 m² clean room floor area

170 m² total area of laboratory facilities




Solopharm production sites

Food supplements

Solopharm food supplements production

V

Solopharm sets the same high-quality requirements for food supplements as for medicines



5 production lines



≈ 4 mln packages per year



Solopharm food supplements production

2 477 m² total production area

667 m² clean room floor area

1,5 MW electrical power of production





Solopharm production sites

3):E

DERIC

1000

Soft forms plant

Solopharm Soft Forms Plant



new modern plant for the production of soft dosage forms (gels, ointments) was launched

1,45 mln packages per year

6

medicines under development and registration and in the process of authorization

SOLOPHARM

production line:

from AFS synthesis to release

ready-made dosage form

Solopharm Soft Forms Plant

V

The design of the production facilities is based on the modular Matrix Wall production system

> Own treatment facilities (wastewater neutralization site)

> Ventilation:

The air treatment system meets international GMP standards, which ensures D class in the rooms

$2240 m^2$

total floor area of the plant

1 250 m²

clean room floor area

400 kW

electrical power of production









21-

IIIIII

Matrix Wall

V

S

New Solopharm project for design, manufacture and installation of clean rooms



Design engineering

Manufacturing

 Installation of clean rooms for the pharmaceutical productions

4

workshops:

- blank production shop
- > welding shop
- > assembly shop
- > packing and kitting area

1 840 m² production areas





ESS warehouse

V

Pharmaceutical warehouse for storage of raw and other materials and final products with built-in administration and amenity facilities and mechanical rooms

15 000 m² warehouse total area

30 000 pallet positions



Licenses:

- For the production of pharmaceuticals for medical use
- date received august 2024
- For the pharmaceutical business operations
- date received may 2024

Technical facilities:

 Cold storage chambers for thermolabile products

SOLOPHARM

 Sampling area of the Quality control department laboratory

Solopharm Points of growth

BioMix Plant

V

S

A plant for the production of biotechnological products with the possibility of expansion in other areas

Q1 2026

planned commercial launch

9,5 bln RUB volume of investments



Solopharm Portfolio

+ >>> SCHUMA >>

0

5

New products

Ophthalmic irrigation solution

BALANSOL SOFT

 Application as a solution for extraocular and intraocular irrigation, as well as for intraocular surgery in the formation of volume and deepening of the anterior chamber of the eye



Ophthalmic moisturizing solution

GYLAN® DEX

[dexpanthenol 2% + sodium hyaluronate 0.18%]

- > Hydration and recovery after surgery and injury
 > Can be used without removing the lenses
- > No preservatives



Ophthalmic moisturizing solution

GYLAN® ULTRADEX

[dexpanthenol 2% + sodium hyaluronate 0.3%]

- > Long-term hydration and recovery after operations and injuries
- > Can be used without removing the lenses
- > No preservatives



Anti-glaucoma drug

BRIMONTIM SOLOPHARM

[brimonidine 2 mg/ml + timolol 5 mg/ml]

 For the treatment of open-angle glaucoma and ophthalmohypertension
 Convenience for the elderly patient: the bottle is equipped with an auxiliary device — strike stop



Anti-glaucoma drug

DORZIAL PLUS

[dorzolamide 20 mg/ml + timolol 5 mg/ml]

- > For the treatment of increased intraocular pressure in open-angle glaucoma
- > Preservative-free composition, safer for the eye surface¹
- > Additional moisturizing effect
- due to the content of sodium hyaluronate¹



 Petrov S.Yu., Kalinina O.M., Zhuravleva A.N., Filippova O.M., Yakubova L.V., Vasilenkova L.V., Kosakyan S.M., Markelova O.I. Efficacy and safety of hypotensive therapy of primary glaucoma with a domestic generic fixed combination of dorzolamide and timolol. Russian Ophthalmological Journal. 2022; 15 (3): 52-60. https://doi.org/10.21516/2072-0076-2022-15-3-52-602.

Mydriatic

STELFRIN SUPRA

[phenylephrine 2.5%]

- For the prevention of asthenopia and accommodation disorders with high visual load
- > No preservatives, which ensures comfort when using¹
- > Enriched with sodium hyaluronic acid to moisturize the eye surface¹



 Tarutta E.P., Tarasova N.A., Milash S.V., Markosyan G.A., Kushnarevich N.Yu., Larina T.Yu. The effect of phenylephrine hydrochloride 2.5% and sodium hyaluronate solution on visual functions and accommodation in children with myopia and its local tolerability. Russian Ophthalmological Journal. 2021; 14 (4): 85-94. https://doi.org/10.21516/2072-0076-2021-14-4-85-94. Q

Gel for the preparation of suspension for oral administration

SOLOSORB



[polymethylsiloxane polyhydrate 100 g]

 Detoxifying agent for adults and children (acute and chronic intoxications of various origins, poisoning, intestinal infections, food and drug allergies, etc.)

Food supplements in sachet-bags

MAGNESIUM AND VITAMIN B6

[magnesium 400 mg, vitamin B6 6 mg and vitamin C 800 mg]

> Promotes:

- concentration of attention and memory improvement
- maintaining the functional state of the heart and blood vessels

Food supplements in sachet-bags

MAGNESIUM AND CALCIUM

[magnesium 400 mg, calcium 800 mg, vitamin D3 15 mcg and C 800 mg]

> Promotes:

÷

- strengthening of bones
- normal functioning of the heart and blood vessels







0

Viscoelastic ophtalmic solution

ADGEVISK® LITE

[sodium hyaluronate 1.7% + chondroitin sulfate 4%]

 > When performing surgeries on the anterior segment of the eye, including cataract extraction and implantation of intraocular lenses



BRONPRIVA SOLOPHARM

[tiotropium bromide 9 mcg/dose]

> As maintenance therapy in adults with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Metered nasal spray / Nasal drops

FRIDIFIN

[dimetindene 35.125 mcg/dose + phenylephrine 351.25 mcg/dose]


[dimethinden 0.25 mg + phenylephrine 2.5 mg]

- Enhanced double action against rhinitis on the background of acute respiratory viral infections (ARVI) land allergies
 - > 100% allergen-free composition*
 - > Thoughtful packaging format

> Vasoconstrictive and antihistamine effects



*There are no essential oils in the composition





Intradermal implant

Q

BELLARTI® ESTILLA

[hyaluronic acid 7.5 mg/ml (0.75%) + polylactic acid 10 mg/ml (1%)]

- > Stimulates collagen production > Prevention of age-related changes in facial proportions > Restores volume in tissues





Muscle relaxant

LIDAMITOL TAB. [tolperizone 150 mg №30]

 Completely bioequivalent to the original drug¹
 The second step in antispasmodic therapy after Lidamitol injections



1. Farmvestnik No. 19 (1148) on August 27, 2024.

Antioxidant of direct and indirect action


ITILOKT[®] BV

[thioctic acid 600 mg №30]

- The only dosage form (Rapid Release)
 that does not have pronounced
 fluctuations in blood plasma
 concentration¹
- Itilokt[®] BV has an antioxidant, neurotrophic effect, improves
 lipid metabolism²



1. Dan Ziegler et al., Oral Treatment With alpha-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-2370. 2. General Characteristics Of The Drug Itilokt BV



Anxiolytic

0

ATREVOZOL®

[fabomotizole 10 mg]

> For anxiety states: neurasthenia, sleep disorders, adaptation disorders, in patients with various somatic diseases, dermatological diseases, etc.



Antidepressant, selective serotonin reuptake inhibitor


CIVELT

[escitalopram 10 mg]

> Antidepressant of choice with a favorable efficacy-safety ratio and minimal drug interactions¹ > Improves patients' qualityof life²



1. S. G. Burchinsky, State Institution «D. F. Chebotarev Institute of Gerontology of NAMS of Ukraine», Kyev, Ukraine/Depression in elderly and senile patients: the problem of choosing an antidepressant drug. 2. Zakharova K. V., Akhapkin R. V. The place of escitalopram in the treatment of depressive and anxiety disorders. RMJ. 2010; 26:1556.



Combined antihypertensive drug

EROFFA

0

[indapamide + perindopril arginine 0.625 mg + 2.5 mg / 1.25 mg + 5 mg / 2.5 mg + 10 mg]

> The first reproduced¹ combination of arginine salt of perindopril and indapamide in vials²

Antihypertensive drug

0

PERINDOPRIL SOLOPHARM [perindopril arginine 5 mg / 10 mg]

> ACE inhibitors* with optimal organoprotection in the form of arginine salt with pronounced advantages over perindopril erbuminom^{3,4}






1. Based on the results of the comparative dissolution kinetics test.

Dased on the results of the comparative dissolution kinetics test.
 According to IQVIA, June 2024.
 D.I. Trukhan. Optimization of drug therapy for coronary heart disease and hypertension: the choice of an angiotensin converting enzyme inhibitor. Systemic hypertension №1, 2014.
 Perindopril arginine: a new salt of an angiotensin-converting enzyme inhibitor expands the possibilities of application. Yu. A. Karpov. 2008.



1. Petunina N.A., Goncharova E.V., Telnova M.E., Trukhina L.V., Martirosyan N.S. Sitagliptin is the world's first inhibitor DPP-4. Medical advice. 2019; 4: 14-19. DAY: https://doi.org/10.21518/2079-701X-2019-4-14-19. 2. Misnikova I. V., Kovaleva Yu. A., Gubkina V. A. Early intensification of hypoglycemic therapy: VERIPY lessons and real clinical practice on the example of data from the diabetes registry of the Moscow region //Problems of endocrinology. – 2020. – vol. 66. – No. 5. – pp. 86-95 "athresoclerotic cardiovascular diseases"

**inhibitor dipeptidyl peptidase-4



Non-steroidal anti-inflammatory drug

FLAGZAMMA

[etoricoxib 60 mg / 90 mg / 120 mg]

> Highly selective NSAID¹ of the new generation with minimal impact on the gastrointestinal tract² > Provides a fast³ and long-lasting analgesic effect when taken in one tablet⁴

Antiallergic drug

LAZAMIRT

0

[desloratadine 5 mg]

> Reducing allergic reactions, itching and swelling





1. Karateev AE. Therapeutic potential of etoricoxib in clinical practice. Modern Rheumatology. 2020;14(1):108–117. DOI: 10.14412/1996-7012-2020-1-108-117 2. Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmaco-logic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol.2018 Nov;28(6):1021-8. doi: 10.1080/14397595.2018.1439694. Epub 2018 Mar 1

3. Malmstrom K, Sapre A, Couglin H, et al. Etoricoxib in acute pain associated with den[1]tal surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study. Clin Ther. 2004 May;26(5):667-79. doi: 10.1016/S0149-2918(04)90067-7

4. Zhang S, Zhang Y, Liu P, et al. Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis. Clin Rheumatol. 2016 Jan;35(1):151-8. doi: 0.1007/s10067-015-2991-1. Epub 2015 Jun 24

Ophthalmology



Antiglaucoma products

Dorzial / Dorzial plus Dorzolan® solo / extra / Trilaktan® Travaxal / Timolol / Betaxolol Taflarint Brimontim solopharm

Metabolic product

Taustin

Eye wash and moisturizing drops

Gylan[®] comfort / Gylan[®] ultra comfort / Gylan[®] extra / Gylan[®] dex / new! Gylan[®] ultradex new! Ocusalin / Biviart[®] comfort / Biviart[®] soft / Biviart[®] ultra

Contact lens solution

AquaOptic

Vasoconstricting product

Sigida® crystal / Oftrix

Anti-allergic products

Sigida duo® / Oloridine Cromicil®



Antimicrobial products

Korfecin / Timilox[®] Lafrax / Sodium Sulfacil-Solopharm / Pictorid

Mydriatic products

Phenycamide® Stelfrin supra

Anticataract products

Oftarint

NSAIDs

Ivinac / Diclofenac

Antioxidants

Vicsipin®

Antiviral

Exinta[®]

Antiseptics

Soloseptin sens



S ENT



products

Otitis treatment products

Lorotox[®] / Otolorin / Niatira

Products for sore throat treatment

Angidak[®] Angidak[®] forte Angidak[®] sept Gelangin[®] nova Gelangin[®] flex

Nasal moisturizing product

Olyfrin

Nasal, mouth, and throat rinsing products

LinAqua Baby / Soft / Norm Forte / Forte for mouth and throat

Rhinitis treatment products

Rhinostain®/ Tramycent Xylokt®-Solopharm Oxyfrin / Ryxint Rhino Ropaxim/ Naximin Babyfrin® / Ivilekt Naphthyzine Fridifin new!



Olyfrin

 Approved by the National Medical Association of Otorhinolaryngologists*
 №1 in the category of drugs for treatment, restoration and protection of the nasal mucosa**

Lorotox®

Nº1 in the recommendations of specialists among ear drops of domestic manufacturers***

Tramycent

Nº1 in the recommendations of ENT doctors in Russia. 50% of all ENT doctors in the Russian Federation choose Tramycent****

Rhinostein®

N₂2 among the fastest growing in tertiary sales of Solopharm nasal brands (+62% YTD 2024 vs 2023)*****

*Russian otorhinolaryngology. 2024; 23(4).

**According to Ipsos prescriptions, 2024, Q1. and sales in kind AlphaRM 2024, Q1-2.

***INN: Lidocaine+Phenazone, Ipsos, 2024, Q1-2.

****Ipsos, 2024.

*****Accoding to AlphaRM, package sales, 32 weeks 2024 vs 32 weeks 2024.



Rheumatology & Traumatology

12 products

Viscosupplement injections

Armaviscon® Vita / Plus / Forte MN / Chondro / Platinum



Double syringe

ACT SOLOPHARM®

Chondroprotectors

Artogystan / Diagistan new!

NSAID

Elox Solopharm Rikling Flagzamma new!

Neurology & Psychiatry

13 products

Nootropic product

Encetron-Solopharm

Antioxidant product

Evrin Itilokt® BV new!

Migraine product

Delmigren new!

Complex of vitamines B

Larigama®

Centrally acting muscle relaxant

Lidamitol Lidamitol tab. new!



Antidepressants

Taniksen solopharm new! Paroxetine solopharm new! Civelt new!

soor

Levetiracetam solopharm Zoltraline solopharm Atrevozol®

Cardiology & Endocrinology

products

Antihypertensive drugs

Moxonidine solopharm new! Amlodipin solopharm new! Perindopril solopharm new!

Combined antihypertensive drug

Eroffa new!



Hypoglycemic drugs

Gliptozan new! Vildagvus new!

Antiplatelet drug

Clopidogrel Solopharm new!

Combined hypoglycemic drug

Gliptozan plus new!

Hypolipidemic drug

Ishenor soc

Pulmonology

products

S



Bronchodilators / inhaler solution

Astmasol[®] Novatron

Bronchodilators / metered-dose inhaler

Astmasol[®] neo Novatron neo Bronpriva solopharm

Inhaled hypertonic solution

Ingasalin® 3% Ingasalin® 6% Ingasalin® forte 7%

Mucolytic product

Beraxol

Cosmetology

products

12

S

Implants intradermal

Bellarti[®] Lift Bellarti[®] Hydrate Bellarti[®] Plus Bellarti[®] Extra Plus Bellarti[®] Amino Bellarti[®] Amino Plus Bellarti[®] Estilla new!



Cosmetic product

Bellarti[®] Oxy

soon

Bellarti® Nucleo 7,5 Bellarti® Nucleo 20 Bellarti® Vita Bellarti® Vita Plus

Hygiene Products



6

Antiseptics

Zilexa sept / Zilexa sept Intim MestaMidin-Sens Daily / Home / Personal

ARD and coronavirus prevention

MestaMidin[®]-nasal







Therapy

12 products



Trekrezan[®] > TOP-5 brands

of the antiviral and immunomodulator category with a market share of 10.3%*

 Nº1 brand among all Solopharm brands by an absolute increase of 34% in rubles**

Immunoadaptogen

Trekrezan® Trekrezan® syrup

Laxative

Picodinar

Antiemetic product

Priontil new!

*According to AlphaRM 2024 Q1. **According to AlphaRM, Sell-out, 34 weeks 2024 and 34 weeks 2023.



Anti-allergic products

Soloneks Lazamirt new!

Novatinden solopharm new!

Heartburn treatment

Viascon

Antiviral product

Oseltamivir Solopharm

SOO

Vitamin D

DeTriFerol (anise / banana / orange flavors)

NSAID

Bumidol®

Enterosorbent

Solosorb soon



Food supplements



products

Vitamin and mineral supplements in stick-packs and sachet-bags

Taprit / Taprit Plus / Trieksin[®] / Rimink / Lacart Plus / Magnesium Active / Chitosan Active / Kidsticks / Nutristicks / Lifozil[®] / Collagen solopharm joint / daily new! Magnesium + Vitamin B6 new! Magnesium + Calcium new!

Vitamin and mineral supplements in capsules

Elentra Nutrition®:

Zn / Zn + Se / Mg / Mg + Ca / Q10 + Vitamin C / Mg + B6 / Inositol / ChondroBase® / I + Tyrosine / 5-HTP + B6, etc

Metabiotics

Actoflor®-C / Actoflor-duo / Actoflor® kids

Bath salt

Magnesium Relax new! Magnesium Kids new!



Ophthalmosurgery

Medical devices





Hospital Segment

72 products

Infusion solutions in BFS polypropylene bottles

Friosterin[®] / Ringer_IV Sodium Chloride_IV Aminocaproic acid Linojekt / Levinoks Tifluksan / Flotidin and etc




Injectables in BFS plastic ampoules

Bupivacaine / Teovexal® / Ondansetron, etc. Injectables In pre-filled syringes

Amrostak solopharm / Icatibant

Injectables in glass ampoules Itilokt / Tricombia / Artogystan, etc.




0 0

ΘΘ

Дублирует на планшетное приложение информацию с КРІ портала

ники посолого 1765ренциотов по состояние на Преднарние дели



finit

Educational projects

We care for our partners with IQ Provision

Pharmaceutical industry experts' community

IQ Provision in numbers

- 86 000 registered users
- 3.5 mln portal visits per year
- **3 000** respondents participating in marketing research
- 100 partner pharmacy chains
- 25 000 webinar participants per year





Platform products

- Lessons and integrated courses about Solopharm products
- Webinars with company experts and opinion leaders
- Articles and news on the topical issues
- Statutory documents base
- Questions and answers from the pharmaceutical community

- Workspace digital awards'23 Winner Category: Educational project
- Smartpharma[®] Awards 2023
 Winner
 Category: Informative and outreach project for pharmacy workers
- «The best portal for pharmacists training» according to the «Green Cross»
 International pharmaceutical awards

Features

- **Integration** with educational portals of the pharmacy chains
- **Creation** of the educational portals
- Implementation of the partner training programs

welcome to **iq-provision.ru**



SoloExpert: experts' assessment in the hospital segment

Educational platform aimed to increase the level of expertise in the hospital segment in various areas – from production to procurement processes

Procurement trainings

in accordance with Federal Laws 44-FZ and 223-FZ

Product trainings:

Solopharm hospital segment

- Platform for the ophthalmic surgeons experience exchange and development
- Library with useful resources to work with

Platform Expert Konstantin A. Perov

>

Director of Autonomous Non-Commercial Organization of Continuing Professional Education Institute of Competitive Technologies

>

Ph.D. in Economics with 20 years of experience in procurement of medical products and devices

soon

soloexpert.ru oplatform update





We discuss trends of the development and challenges of the pharmaceutical industry at SoloPharmShow

- Show about the pharmaceutical market from the first hand of the people who create this market
- Platform for discussing the hottest trends, current news and issues in the pharmaceutical market
- Reportages and small-talks like a FUN show

Do you want to participate?

We are looking for great speakers who are ready to discuss current challenges and trends in the development of the pharmaceutical industry to create new episodes.

- > 500 minutes of useful content
- > 25 TOP-speakers from the pharmaceutical and medical community
- > 4 reportages from Solopharm production
- > 20 relevant topics about the development of the pharmaceutical industry



NB! Email us: konstantin.lysenko@grotexmed.com

scan and watch the Show



Solopharm

We care for people

GROTEX LLC

Headquaters:

27 Lvovskaya Street (Office L27 Business Center), St. Petersburg

Office:

10 Butyrsky Val Street (White Square Business Center), Moscow

Manufacturing sites:

71 Industrialnyl Ave., Bldg. 2, lit. A, St. Petersburg13 Lapinsky Lane, lit. Zh St. Petersburg

R&D Laboratory: 69 Revolutsii Highway, Bldg. 102,

(Potapov Business Center), St. Petersburg

General contacts: tel.: +7 812 385 47 87

grtx@grotexmed.com

solopharm.com





